Mölndal, Sweden 19th June 2006.

Investor Growth Capital and CapMan invest in Neoventa Medical AB, a Swedish medical technology company within the area of fetal monitoring. Following these investments, CapMan and Investor Growth Capital will each have an approximately 30% stake in Neoventa. The majority of the other shares will be retained by SEB Företagsinvest. The new shareholder structure will together secure a total capital injection of SEK 75 million that will finance the next phase of growth for Neoventa with a focus on the US market.

Neoventa’s core product STAN® has been shown to significantly reduce the risk that a fetus will suffer from oxygen deficiency and brain injury during childbirth. STAN® works by analysing the shape of the ECG waveform of the fetus during delivery. Changes in fetal ECG shape are an indicator of oxygen deficiency and this information helps clinicians make more informed decisions for intervention. STAN® is currently used in 22 countries and in approximately 100,000 deliveries each year. STAN® was recently approved by the US Food and Drug Administration (FDA), opening up the world’s largest market for fetal monitoring. Neoventa has 19 employees and is based in Mölndal, Sweden.

‘Neoventa is a small, highly specialised company with a superior technology in a market currently dominated by large players. With the support of our new and existing owners we will continue to take market share in Europe and introduce STAN® to new markets. We look forward to working with both Investor Growth Capital and CapMan’ said Simon Grant, CEO for Neoventa.

‘Our review of the extensive published clinical data confirmed our belief that STAN® offers significant advantages over existing methods. FDA approval and new studies including some 50,000 patients provide further positive support for STAN® that will drive clinical acceptance’ said Thomas Eklund from Investor Growth Capital.

‘Neoventa has achieved a user-base of over 350 hospitals - a strong foothold for further growth. Neoventa has great potential to establish a new standard of care in the maternity care market. The demand for the product is very strong and STAN® will be instrumental in millions of births in the future securing an uneventful delivery’ said Johan Bennarsten, CapMan.

Björn Österlund representing SEB Företagsinvest who has been a major shareholder in Neoventa since 1999 adds ‘The last years strategic work has been incredibly important for the company’s strong clinical and technical base, an achievement we would never have reached without Neoventa's great team in Mölndal. It is with strong confidence that we will now continue to expand the business into new markets together with financially strong new co-owners’.

Neoventa Medical
Neoventa Medical AB is a privately...